Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress

Oncogene

Volumn 34, Issue 29, 2015, Pages 3839-3847

  Chen, Y ^a,b   Zhang, Z ^a   Yang, K ^a   Du, J ^c   Xu, Y ^a   Liu, S ^b  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b RESEARCH CENTER FOR ECO ENVIRONMENTAL SCIENCES   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FERROPORTIN; IRON; MICRORNA; MICRORNA 492; MYELOID ZINC FINGER 1 PROTEIN; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; 3' UNTRANSLATED REGION; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CATION TRANSPORT PROTEIN; FERRITIN; KRUPPEL LIKE FACTOR; METAL TRANSPORTING PROTEIN 1; MIRN492 MICRORNA, HUMAN; MZF1 PROTEIN, HUMAN; PROTEIN C MYB; REPIN1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL COUNT; CELL MIGRATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA REPLICATION; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE C MYB; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR VOLUME; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

MAMMALIA;

3' UNTRANSLATED REGIONS; ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CATION TRANSPORT PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FERRITINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IRON; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYB; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

EID: 84937518150     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.310     Document Type: Article

References (53)

1. Hromas R, Collins SJ, Hickstein D, Raskind W, Deaven LL, O'Hara P et al. A retinoic acid-responsive human zinc finger gene, MZF-1, preferentially expressed in myeloid cells. J Biol Chem 1991; 266: 14183-14187.
2. Perrotti D, Melotti P, Skorski T, Casella I, Peschle C, Calabretta B. Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity. Mol Cell Biol 1995; 15: 6075-6087.
3. Hromas R, Boswell S, Shen RN, Burgess G, Davidson A, Cornetta K et al. Forced over-expression of the myeloid zinc finger gene MZF-1 inhibits apoptosis and promotes oncogenesis in interleukin-3-dependent FDCP.1 cells. Leukemia 1996; 10: 1049-1050.
4. Hsieh YH, Wu TT, Tsai JH, Huang CY, Hsieh YS, Liu JY. PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells. Biochem Biophys Res Commun 2006; 339: 217-225.
5. Mudduluru G, Vajkoczy P, Allgayer H. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res 2010; 8: 159-169.
6. Rafn B, Nielsen CF, Andersen SH, Szyniarowski P, Corcelle-Termeau E, Valo E et al. ErbB2-driven breast cancer cell invasion depends on a complex signaling network activating myeloid zinc finger-1-dependent cathepsin B expression. Mol Cell 2012; 45: 764-776.
7. Deng Y, Wang J, Wang G, Jin Y, Luo X, Xia X et al. p55PIK transcriptionally activated by MZF1 promotes colorectal cancer cell proliferation. Biomed Res Int 2013; 2013: 868131.
8. Gaboli M, Kotsi PA, Gurrieri C, Cattoretti G, Ronchetti S, Cordon-Cardo C et al. Mzf1 controls cell proliferation and tumorigenesis. Genes Dev 2001; 15: 1625-1630.
9. Tsai SJ, Hwang JM, Hsieh SC, Ying TH, Hsieh YH. Overexpression of myeloid zinc finger 1 suppresses matrix metalloproteinase-2 expression and reduces invasiveness of SiHa human cervical cancer cells. Biochem Biophys Res Commun 2012; 425: 462-467.
10. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004; 306: 2090-2093.
11. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metabol 2005; 1: 191-200.
12. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-781.
13. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000; 275: 19906-19912.
14. Ward DM, Kaplan J. Ferroportin-mediated iron transport: expression and regulation. Biochim Biophys Acta 2012; 1823: 1426-1433.
15. Troadec MB, Ward DM, Lo E, Kaplan J, De Domenico I. Induction of FPN1 transcription by MTF-1 reveals a role for ferroportin in transition metal efflux. Blood 2010; 116: 4657-4664.
16. Taylor M, Qu A, Anderson ER, Matsubara T, Martin A, Gonzalez FJ et al. Hypoxiainducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology 2011; 140: 2044-2055.
17. Marro S, Chiabrando D, Messana E, Stolte J, Turco E, Tolosano E et al. Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter. Haematologica 2010; 95: 1261-1268.
18. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2010; 2: 43ra56.
19. Choi JY, Neuhouser ML, Barnett MJ, Hong CC, Kristal AR, Thornquist MD et al. Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort. Carcinogenesis 2008; 29: 964-970.
20. Ornstein DL, Zacharski LR. Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells. Nutr Cancer 2007; 58: 115-126.
21. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 2004; 117: 285-297.
22. Wu Y, Brosh RM Jr. DNA helicase and helicase-nuclease enzymes with a conserved iron-sulfur cluster. Nucleic Acids Res 2012; 40: 4247-4260.
23. Brzoska K, Meczynska S, Kruszewski M. Iron-sulfur cluster proteins: electron transfer and beyond. Acta Biochim Pol 2006; 53: 685-691.
24. Rouault TA, Tong WH. Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 2005; 6: 345-351.
25. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta 2009; 1790: 702-717.
26. Heath JL, Weiss JM, Lavau CP, Wechsler DS. Iron deprivation in cancer-potential therapeutic implications. Nutrients 2013; 5: 2836-2859.
27. Donnianni RA, Symington LS. Break-induced replication occurs by conservative DNA synthesis. Proc Natl Acad Sci USA 2013; 110: 13475-13480.
28. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell 2006; 21: 533-542.
29. von Frowein J, Pagel P, Kappler R, von Schweinitz D, Roscher A, Schmid I. MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. Hepatology 2011; 53: 833-842.
30. Gaedcke J, Grade M, Camps J, Sokilde R, Kaczkowski B, Schetter AJ et al. The rectal cancer microRNAome-microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res 2012; 18: 4919-4930.
31. Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T et al. MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol 2012; 25: 1609-1622.
32. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
33. Clapp RW, Jacobs MM, Loechler EL. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health 2008; 23: 1-37.
34. Buschemeyer WC 3rd, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 2007; 52: 331-343.
35. Yuan Y, Ferguson LR. Nutrigenetics and prostate cancer: 2011 and beyond. J Nutrigenet Nutrigenomics 2011; 4: 121-136.
36. Huang X. Does iron have a role in breast cancer? Lancet Oncol 2008; 9: 803-807.
37. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988; 319: 1047-1052.
38. Knekt P, Reunanen A, Takkunen H, Aromaa A, Heliovaara M, Hakulinen T. Body iron stores and risk of cancer. Int J Cancer 1994; 56: 379-382.
39. Cross AJ, Sinha R, Wood RJ, Xue X, Huang WY, Yeager M et al. Iron homeostasis and distal colorectal adenoma risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Prev Res (Phila) 2011; 4: 1465-1475.
40. Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res 2011; 71: 6728-6737.
41. Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer 2013; 13: 342-355.
42. Zhang S, Chen Y, Guo W, Yuan L, Zhang D, Xu Y et al. Disordered hepcidinferroportin signaling promotes breast cancer growth. Cell Signal 2014; 26: 2539-2550.
43. Greig KT, de Graaf CA, Murphy JM, Carpinelli MR, Pang SH, Frampton J et al. Critical roles for c-Myb in lymphoid priming and early B-cell development. Blood 2010; 115: 2796-2805.
44. Lutwyche JK, Keough RA, Hunter J, Coles LS, Gonda TJ. DNA binding-independent transcriptional activation of the vascular endothelial growth factor gene (VEGF) by the Myb oncoprotein. Biochem Biophys Res Commun 2006; 344: 1300-1307.
45. Hugo H, Cures A, Suraweera N, Drabsch Y, Purcell D, Mantamadiotis T et al. Mutations in the MYB intron I regulatory sequence increase transcription in colon cancers. Genes Chromosomes Cancer 2006; 45: 1143-1154.
46. Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. PLoS One 2010; 5: e13073.
47. Egawa T, Littman DR. Transcription factor AP4 modulates reversible and epigenetic silencing of the Cd4 gene. Proc Natl Acad Sci USA 2011; 108: 14873-14878.
48. Mermod N, Williams TJ, Tjian R. Enhancer binding factors AP-4 and AP-1 act in concert to activate SV40 late transcription in vitro. Nature 1988; 332: 557-561.
49. Jung P, Hermeking H. The c-MYC-AP4-p21 cascade. Cell Cycle 2009; 8: 982-989.
50. Jung P, Menssen A, Mayr D, Hermeking H. AP4 encodes a c-MYC-inducible repressor of p21. Proc Natl Acad Sci USA 2008; 105: 15046-15051.
51. Jackstadt R, Roh S, Neumann J, Jung P, Hoffmann R, Horst D et al. AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer. J Exp Med 2013; 210: 1331-1350.
52. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401-1414.
53. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-6424.